• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Outset Medical Welcomes Jean-Olivier Racine as Chief Technology Officer

    6/23/21 9:00:00 AM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $OM alert in real time by email

    Former Head of Engineering and Science for Health AI at Amazon Web Services Joins Dialysis Technology Innovation Leader

    Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a dialysis technology innovator, today announced the appointment of Jean-Olivier Racine as Chief Technology Officer. In this new role, Racine will oversee the strategic advancement of Outset's product technology, amplifying the company's data-driven innovation engine to further elevate the patient care experience and drive operating efficiencies for providers.

    Racine joins Outset Medical with more than two decades of experience in the technology industry. Prior to joining Outset, he worked as the head of engineering and science for Amazon Web Services (AWS) Health AI where he managed Amazon Comprehend Medical, Amazon HealthLake and a variety of health services in development.

    "Jean-Olivier's knowledge of the development of high-scale and high-availability services for the storage of health data, such as HealthLake, is critical to the innovation initiatives we intend to pursue in order to empower patients and healthcare providers," said Outset Medical CEO Leslie Trigg. "His background in designing scalable and performant cloud architectures for at-home health and consumer products, such as Amazon Halo and Fire TV, and in using machine learning for retrieving health insights from data, such as Comprehend Medical, will be invaluable as we continue to invent in ways that uplift the dialysis patient population."

    As the industry's only hemodialysis technology cleared by the FDA for two-way wireless data transmission, Outset's Tablo Hemodialysis System sends patient treatment data seamlessly to electronic medical record systems and also to TabloHub, a proprietary cloud-based provider portal that aggregates all patient and Tablo fleet records. At the same time, Tablo captures more than 500,000 machine performance data points after every treatment. That information is then used to fuel data analytics and machine learning algorithms that, in this new role, Racine will utilize to continually improve the technology, create service efficiencies and uncover new opportunities.

    Racine spent almost ten years in a variety of Amazon leadership positions, including as the head of science and engineering for AWS Health AI, head of cloud services and Alexa for Halo, head of the Digital Media Catalog for Fire TV, and as the fluidity and performance lead for Kindle Fire tablets. Before joining Amazon, Racine spent more than a decade in software engineering for companies such as the Toronto Stock Exchange (TMX), NexGen Ergonomics, Versaterm and Canada's Department of National Defense. Racine earned both his bachelor's degree in production automation engineering, health technologies and his master's degree in engineering, health technologies from the Université du Québec - École de technologie supérieure.

    "I was drawn to join Outset Medical because of the vast opportunity the dialysis industry presents, especially with regards to utilizing technology and AI for the development of new care modalities," said Racine. "Throughout my career I have seen the progress the health tech industry has made as artificial intelligence, machine learning and the consumer driven digital experience has become a reality for numerous patient populations. I look forward to using my expertise to build upon the incredible strides Outset has already made with Tablo, and to create new efficiencies for patients and providers as we continue to move towards a tech-enabled future."

    About Outset Medical, Inc.

    Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo™ Hemodialysis System, FDA cleared for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers. Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels with 2-way wireless data transmission and a proprietary data analytics platform powering a new holistic approach to dialysis care. Tablo is a registered trademark of Outset Medical, Inc.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20210623005125/en/

    Get the next $OM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OM

    DatePrice TargetRatingAnalyst
    8/8/2024$6.00 → $3.00Outperform → Sector Perform
    RBC Capital Mkts
    6/21/2024$5.00 → $6.00Sector Perform → Outperform
    RBC Capital Mkts
    4/8/2024$6.00Buy
    BTIG Research
    4/5/2024$6.00Neutral → Buy
    CL King
    1/12/2024$14.00 → $6.00Outperform → Sector Perform
    RBC Capital Mkts
    10/13/2023$32.00 → $3.00Buy → Underperform
    BofA Securities
    8/17/2023Neutral
    CL King
    11/11/2022$23.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $OM
    SEC Filings

    View All

    SEC Form 144 filed by Outset Medical Inc.

    144 - Outset Medical, Inc. (0001484612) (Subject)

    8/15/25 7:57:18 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Outset Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Outset Medical, Inc. (0001484612) (Filer)

    8/6/25 4:15:10 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SCHEDULE 13G filed by Outset Medical Inc.

    SCHEDULE 13G - Outset Medical, Inc. (0001484612) (Subject)

    7/29/25 2:14:28 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $OM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Outset Medical downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded Outset Medical from Outperform to Sector Perform and set a new price target of $3.00 from $6.00 previously

    8/8/24 6:47:35 AM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Outset Medical upgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts upgraded Outset Medical from Sector Perform to Outperform and set a new price target of $6.00 from $5.00 previously

    6/21/24 6:53:06 AM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BTIG Research initiated coverage on Outset Medical with a new price target

    BTIG Research initiated coverage of Outset Medical with a rating of Buy and set a new price target of $6.00

    4/8/24 7:26:20 AM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $OM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chair and CEO Trigg Leslie sold $11,644 worth of shares (904 units at $12.88), decreasing direct ownership by 0.73% to 122,328 units (SEC Form 4)

    4 - Outset Medical, Inc. (0001484612) (Issuer)

    8/18/25 4:05:30 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SVP Operations and R&D Nash Marc sold $3,130 worth of shares (243 units at $12.88), decreasing direct ownership by 0.56% to 42,898 units (SEC Form 4)

    4 - Outset Medical, Inc. (0001484612) (Issuer)

    8/18/25 4:01:44 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    General Counsel Brottem John L. sold $4,933 worth of shares (383 units at $12.88), decreasing direct ownership by 0.81% to 46,883 units (SEC Form 4)

    4 - Outset Medical, Inc. (0001484612) (Issuer)

    8/18/25 4:00:16 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $OM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Outset Medical to Present at the 23rd Annual Morgan Stanley Global Healthcare Conference

    SAN JOSE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that management will present at the 23rd annual Morgan Stanley Global Healthcare Conference on Wednesday, Sept. 10, 2025, at 7 a.m. Eastern time. A live and archived webcast of the presentation will be available on the "Investors" section of the Outset website at https://investors.outsetmedical.com/. About Outset Medical, Inc. Outset is a medical technology company transforming the dialysis experience across the continuum of care with a first-of-its-kind techno

    8/20/25 4:05:00 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Outset Medical Second-Quarter Results Demonstrate Continued Momentum, Punctuated by Strong Revenue Growth, Console Placements and Utilization

    SAN JOSE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the second quarter ended June 30, 2025. Second Quarter and Recent Highlights Net revenue of $31.4 million grew 15% from the prior-year period, driven by a 25% increase in Tablo console revenue.Recurring revenue consisting of Tablo consumables and services grew 11% over the prior-year period to $22.5 million, driven by a 17% increase in consumable revenue.Gross margin was 37.8%, or 38.4% on a non-GAAP basis, a 110 basis-point improvement over the prior

    8/6/25 4:02:00 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Outset Medical Names First Chief Nursing Officer

    SAN JOSE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced Brittni McGill has been named to the newly created role of Chief Nursing Officer where she will apply her extensive nurse executive leadership experience to help increase strategic outreach and clinical program innovation designed to empower nurses and nurse leaders and elevate care. "Our entire Outset team understands and celebrates the critical role the nursing community and specifically, nurse executives, play in ensuring successful patient outcomes across

    7/30/25 9:01:00 AM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $OM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Outset Medical Inc.

    SC 13G/A - Outset Medical, Inc. (0001484612) (Subject)

    11/12/24 4:53:46 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Outset Medical Inc.

    SC 13G/A - Outset Medical, Inc. (0001484612) (Subject)

    11/12/24 4:26:01 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Outset Medical Inc.

    SC 13G/A - Outset Medical, Inc. (0001484612) (Subject)

    11/12/24 10:32:13 AM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $OM
    Financials

    Live finance-specific insights

    View All

    Outset Medical Second-Quarter Results Demonstrate Continued Momentum, Punctuated by Strong Revenue Growth, Console Placements and Utilization

    SAN JOSE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the second quarter ended June 30, 2025. Second Quarter and Recent Highlights Net revenue of $31.4 million grew 15% from the prior-year period, driven by a 25% increase in Tablo console revenue.Recurring revenue consisting of Tablo consumables and services grew 11% over the prior-year period to $22.5 million, driven by a 17% increase in consumable revenue.Gross margin was 37.8%, or 38.4% on a non-GAAP basis, a 110 basis-point improvement over the prior

    8/6/25 4:02:00 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Outset Medical to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

    SAN JOSE, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the second quarter 2025 after the close of trading on Wednesday, August 6, 2025. On the same day, at 2:00 p.m. Pacific time (5:00 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Renee Gaeta, Chief Financial Officer, will host a conference call to discuss financial and operating results. Conference Call DetailsThe conference call will begin at 2:00 p.m. Pacific time (5:00 p.m. Eastern time) on W

    7/16/25 4:03:00 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Outset Medical First-Quarter Results Demonstrate Strong Growth in Console and Recurring Revenue as Gross Margin Expanded and Cash Use Declined

    SAN JOSE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the first quarter ended March 31, 2025. First Quarter and Recent Highlights Net revenue of $29.8 million grew 6% from the prior-year period.Tablo console revenue grew 23% from the fourth quarter.Recurring revenue consisting of Tablo consumables and services grew 20% over the prior-year period to $22.7 million. Outset shipped its 3 millionth Tablo treatment during the quarter, adding 1 million treatments over a period of approximately 12 months.Gross ma

    5/7/25 4:02:00 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $OM
    Leadership Updates

    Live Leadership Updates

    View All

    Outset Medical Appoints Industry Veteran Kevin O'Boyle to its Board of Directors

    SAN JOSE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the appointment of healthcare industry veteran Kevin O'Boyle to its Board of Directors and as chair of its Audit Committee. With Mr. O'Boyle's appointment, the company also announced that Dale E. Jones has stepped down from the Board. "Kevin's over 20 years of healthcare leadership experience span roles as CFO of several publicly traded companies and as a board director of 6 public medical device companies," said Leslie Trigg, Chair and CEO. "His expertise in c

    5/14/25 9:00:00 AM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Masimo Announces Leadership Transition

    Katie Szyman Appointed Chief Executive Officer and to Board of Directors Interim CEO Michelle Brennan Named Chairman of Masimo's Board Today the Board of Directors (the "Board") of Masimo (NASDAQ:MASI), a leading global medical innovator, announced that Katie Szyman has been appointed the next Chief Executive Officer ("CEO") of the Company. Interim CEO Michelle Brennan has been appointed Chairman of Masimo's Board and Lead Independent Director Quentin Koffey has been appointed Vice Chairman. All of these changes are effective as of February 12, 2025. Ms. Szyman is currently worldwide president of Advanced Patient Monitoring at BD (Becton, Dickinson and Company). Previously, Ms. Szyman

    1/21/25 4:00:00 PM ET
    $MASI
    $NARI
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medical/Dental Instruments

    Outset Medical Names Business Leader Dale E. Jones to Board of Directors

    Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company reducing the cost and complexity of dialysis, today announced the appointment of Dale E. Jones to its Board of Directors. "Dale brings more than 30 years of experience in building diverse and dynamic teams to Outset at a time of exceptional growth for our team," said Chair and CEO Leslie Trigg. "He leads with purpose and deeply understands the role values and culture play in building high-performance organizations, critical traits as we focus on transforming dialysis." Mr. Jones is a Senior Advisor at Diversified Search Group, and previously served as its CEO for more than eight years. He began his career in banking

    4/25/22 4:00:00 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care